(Q28237419)

Cancer immunoediting: from immunosurveillance to tumor escape

31 March 2020

1 reference

Observing the invisible: successful tumor immunity in humans

31 March 2020

1 reference

Paraneoplastic Syndromes Involving the Nervous System

31 March 2020

1 reference

Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour

31 March 2020

1 reference

Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies

31 March 2020

1 reference

Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy

31 March 2020

1 reference

Paraneoplastic cerebellar degeneration: clinical-immunological correlations

31 March 2020

1 reference

Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume.

31 March 2020

1 reference

Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients

31 March 2020

1 reference

Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients

31 March 2020

1 reference

Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma

31 March 2020

1 reference

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.

31 March 2020

1 reference

The importance of defining the paraneoplastic neurologic disorders

31 March 2020

1 reference

Paraneoplasia and autoimmunologic injury of the nervous system: the anti-Hu syndrome

31 March 2020

1 reference

Normalization of the Tumor Marker CA-125 after Oophorectomy in a Patient with Paraneoplastic Cerebellar Degeneration without Detectable Cancer

31 March 2020

1 reference

Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies

31 March 2020

1 reference

Spontaneous regression of small cell carcinoma of lung associated with severe neuropathy

31 March 2020

1 reference

Spontaneous neurological improvement in anti-Hu associated encephalomyelitis

31 March 2020

1 reference

Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration.

31 March 2020

1 reference

Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy

31 March 2020

1 reference

Cerebellar degeneration with Hodgkin disease. An immunological study

31 March 2020

1 reference

Sensory neuropathy with bronchial carcinoma: a study of four cases showing serological abnormalities.

31 March 2020

1 reference

Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen

31 March 2020

1 reference

Partial characterization of the Purkinje cell antigens in paraneoplastic cerebellar degeneration

31 March 2020

1 reference

Neuronal antinuclear antibody in sensory neuronopathy from lung cancer.

31 March 2020

1 reference

Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor

31 March 2020

1 reference

Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes

31 March 2020

1 reference

Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain

31 March 2020

1 reference

Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration

31 March 2020

1 reference

Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer

31 March 2020

1 reference

The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival

31 March 2020

1 reference

A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues

31 March 2020

1 reference

Nova regulates GABA(A) receptor gamma2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer

31 March 2020

1 reference

The splice of life: alternative splicing and neurological disease

31 March 2020

1 reference

Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability

31 March 2020

1 reference

31 March 2020

HuR and mRNA stability

1 reference

Why is Hu where? Shuttling of early-response-gene messenger RNA subsets

31 March 2020

1 reference

Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration.

31 March 2020

1 reference

Hu antigens: Reactivity with hu antibodies, tumor expression, and major immunogenic sites

31 March 2020

1 reference

Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer?A quantitative western blot analysis

31 March 2020

1 reference

Regulation of class I MHC gene expression in the developing and mature CNS by neural activity

31 March 2020

1 reference

Immunologic complexity in neurons

31 March 2020

1 reference

Tumor-specific killer cells in paraneoplastic cerebellar degeneration

31 March 2020

1 reference

Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration

31 March 2020

1 reference

T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis.

31 March 2020

1 reference

A hierarchy of Hu RNA binding proteins in developing and adult neurons.

31 March 2020

1 reference

Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system

31 March 2020

1 reference

The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies

31 March 2020

1 reference

Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay

31 March 2020

1 reference

Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes

31 March 2020

1 reference

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

31 March 2020

1 reference

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes

31 March 2020

1 reference

Cross-presentation in viral immunity and self-tolerance.

31 March 2020

1 reference

CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs

31 March 2020

1 reference

Leukocyte migration: scent of the T zone

31 March 2020

1 reference

Dendritic cells and the control of immunity

31 March 2020

1 reference

Cross-presentation, dendritic cells, tolerance and immunity

31 March 2020

1 reference

Antigen presentation and T cell stimulation by dendritic cells

31 March 2020

1 reference

Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help

31 March 2020

1 reference

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

31 March 2020

1 reference

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

31 March 2020

1 reference

Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy

31 March 2020

1 reference

alphavbeta5 integrin recruits the CrkII-Dock180-rac1 complex for phagocytosis of apoptotic cells

31 March 2020

1 reference

Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells

31 March 2020

1 reference

Constitutive class I-restricted exogenous presentation of self antigens in vivo

31 March 2020

1 reference